NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multidrug resistance (MDR) significantly hinders cancer chemotherapy efficacy.
• Existing strategies to overcome MDR have not yielded effective therapies.
• Novel agents are crucial for both clinical and scientific advancements in cancer treatment.

Purpose of the Study:

• To identify small molecule compounds capable of reversing chemoresistance.
• To investigate the potential of novel agents in overcoming MDR in cancer.

Main Methods:

• A high-throughput cell-based screening assay was developed using paclitaxel-resistant ovarian cancer cells.
• 2,000 small molecules from the National Cancer Institute Diversity Set Library were screened.
• The activity of identified compounds was evaluated in cancer cell lines expressing Pgp1, MRP, and BCRP.

Main Results:

• NSC23925 was identified as a novel molecule that inhibits P-glycoprotein (Pgp1) and reverses Pgp1-mediated MDR.
• NSC23925 demonstrated moderate inhibition of proliferation in sensitive and resistant cell lines.
• NSC23925 increased intracellular accumulation of Pgp1 substrates and stimulated Pgp ATPase activity.

Conclusions:

• NSC23925 shows potential to restore sensitivity to chemotherapy and prevent resistance.
• This agent could significantly benefit cancer patients by improving treatment outcomes.
• Further research into NSC23925 may lead to improved MDR reversal strategies.